The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...

Shares of Novo Nordisk surged after the Danish drugmaker struck an agreement with CVS Health that will let its pharmacy-benefit manager, CVS Caremark, favor the company's weight-loss medication Wegovy ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Novo Nordisk NVO is expected to beat estimates ... studies for NVO’s next-generation subcutaneous obesity candidate, CagriSema, a follow-up drug to Wegovy. Earlier this month, Medicare ...

Novo Nordisk NVO is expected to beat estimates when it reports its first-quarter 2025 results before the opening bell on May ...

When the stock market experiences a sharp decline, as it did after the Trump administration announced tariffs on its trade partners and China responded with retaliatory tariffs, many investors start ...